Copyright Reports & Markets. All rights reserved.

Global Antisense Oligonucleotides Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Antisense Oligonucleotides
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Antisense Oligonucleotides by Type
    • 1.3.1 Overview: Global Antisense Oligonucleotides Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Antisense Oligonucleotides Consumption Value Market Share by Type in 2022
    • 1.3.3 RNA Antisense Oligonucleotides
    • 1.3.4 DNA Antisense Oligonucleotides
  • 1.4 Global Antisense Oligonucleotides Market by Application
    • 1.4.1 Overview: Global Antisense Oligonucleotides Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospitals
    • 1.4.3 Clinic
    • 1.4.4 Others
  • 1.5 Global Antisense Oligonucleotides Market Size & Forecast
  • 1.6 Global Antisense Oligonucleotides Market Size and Forecast by Region
    • 1.6.1 Global Antisense Oligonucleotides Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Antisense Oligonucleotides Market Size by Region, (2018-2029)
    • 1.6.3 North America Antisense Oligonucleotides Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Antisense Oligonucleotides Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Antisense Oligonucleotides Market Size and Prospect (2018-2029)
    • 1.6.6 South America Antisense Oligonucleotides Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Antisense Oligonucleotides Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Ionis Pharmaceuticals
    • 2.1.1 Ionis Pharmaceuticals Details
    • 2.1.2 Ionis Pharmaceuticals Major Business
    • 2.1.3 Ionis Pharmaceuticals Antisense Oligonucleotides Product and Solutions
    • 2.1.4 Ionis Pharmaceuticals Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Ionis Pharmaceuticals Recent Developments and Future Plans
  • 2.2 Sarepta Therapeutics
    • 2.2.1 Sarepta Therapeutics Details
    • 2.2.2 Sarepta Therapeutics Major Business
    • 2.2.3 Sarepta Therapeutics Antisense Oligonucleotides Product and Solutions
    • 2.2.4 Sarepta Therapeutics Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Sarepta Therapeutics Recent Developments and Future Plans
  • 2.3 Biogen
    • 2.3.1 Biogen Details
    • 2.3.2 Biogen Major Business
    • 2.3.3 Biogen Antisense Oligonucleotides Product and Solutions
    • 2.3.4 Biogen Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Biogen Recent Developments and Future Plans
  • 2.4 Alnylam Pharmaceuticals
    • 2.4.1 Alnylam Pharmaceuticals Details
    • 2.4.2 Alnylam Pharmaceuticals Major Business
    • 2.4.3 Alnylam Pharmaceuticals Antisense Oligonucleotides Product and Solutions
    • 2.4.4 Alnylam Pharmaceuticals Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
  • 2.5 Antisense Therapeutics
    • 2.5.1 Antisense Therapeutics Details
    • 2.5.2 Antisense Therapeutics Major Business
    • 2.5.3 Antisense Therapeutics Antisense Oligonucleotides Product and Solutions
    • 2.5.4 Antisense Therapeutics Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Antisense Therapeutics Recent Developments and Future Plans
  • 2.6 Isarna Therapeutics
    • 2.6.1 Isarna Therapeutics Details
    • 2.6.2 Isarna Therapeutics Major Business
    • 2.6.3 Isarna Therapeutics Antisense Oligonucleotides Product and Solutions
    • 2.6.4 Isarna Therapeutics Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Isarna Therapeutics Recent Developments and Future Plans
  • 2.7 Arrowhead Pharmaceuticals
    • 2.7.1 Arrowhead Pharmaceuticals Details
    • 2.7.2 Arrowhead Pharmaceuticals Major Business
    • 2.7.3 Arrowhead Pharmaceuticals Antisense Oligonucleotides Product and Solutions
    • 2.7.4 Arrowhead Pharmaceuticals Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Arrowhead Pharmaceuticals Recent Developments and Future Plans
  • 2.8 Atlantic Pharmaceuticals
    • 2.8.1 Atlantic Pharmaceuticals Details
    • 2.8.2 Atlantic Pharmaceuticals Major Business
    • 2.8.3 Atlantic Pharmaceuticals Antisense Oligonucleotides Product and Solutions
    • 2.8.4 Atlantic Pharmaceuticals Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Atlantic Pharmaceuticals Recent Developments and Future Plans
  • 2.9 Enzon Pharmaceuticals
    • 2.9.1 Enzon Pharmaceuticals Details
    • 2.9.2 Enzon Pharmaceuticals Major Business
    • 2.9.3 Enzon Pharmaceuticals Antisense Oligonucleotides Product and Solutions
    • 2.9.4 Enzon Pharmaceuticals Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Enzon Pharmaceuticals Recent Developments and Future Plans
  • 2.10 Bio-Path Holdings
    • 2.10.1 Bio-Path Holdings Details
    • 2.10.2 Bio-Path Holdings Major Business
    • 2.10.3 Bio-Path Holdings Antisense Oligonucleotides Product and Solutions
    • 2.10.4 Bio-Path Holdings Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Bio-Path Holdings Recent Developments and Future Plans
  • 2.11 GlaxoSmithKline
    • 2.11.1 GlaxoSmithKline Details
    • 2.11.2 GlaxoSmithKline Major Business
    • 2.11.3 GlaxoSmithKline Antisense Oligonucleotides Product and Solutions
    • 2.11.4 GlaxoSmithKline Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 GlaxoSmithKline Recent Developments and Future Plans
  • 2.12 Geron
    • 2.12.1 Geron Details
    • 2.12.2 Geron Major Business
    • 2.12.3 Geron Antisense Oligonucleotides Product and Solutions
    • 2.12.4 Geron Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Geron Recent Developments and Future Plans
  • 2.13 ICO Therapeutics
    • 2.13.1 ICO Therapeutics Details
    • 2.13.2 ICO Therapeutics Major Business
    • 2.13.3 ICO Therapeutics Antisense Oligonucleotides Product and Solutions
    • 2.13.4 ICO Therapeutics Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 ICO Therapeutics Recent Developments and Future Plans
  • 2.14 Marina Biotech
    • 2.14.1 Marina Biotech Details
    • 2.14.2 Marina Biotech Major Business
    • 2.14.3 Marina Biotech Antisense Oligonucleotides Product and Solutions
    • 2.14.4 Marina Biotech Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Marina Biotech Recent Developments and Future Plans
  • 2.15 RXi Pharmaceuticals
    • 2.15.1 RXi Pharmaceuticals Details
    • 2.15.2 RXi Pharmaceuticals Major Business
    • 2.15.3 RXi Pharmaceuticals Antisense Oligonucleotides Product and Solutions
    • 2.15.4 RXi Pharmaceuticals Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 RXi Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Antisense Oligonucleotides Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Antisense Oligonucleotides by Company Revenue
    • 3.2.2 Top 3 Antisense Oligonucleotides Players Market Share in 2022
    • 3.2.3 Top 6 Antisense Oligonucleotides Players Market Share in 2022
  • 3.3 Antisense Oligonucleotides Market: Overall Company Footprint Analysis
    • 3.3.1 Antisense Oligonucleotides Market: Region Footprint
    • 3.3.2 Antisense Oligonucleotides Market: Company Product Type Footprint
    • 3.3.3 Antisense Oligonucleotides Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Antisense Oligonucleotides Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Antisense Oligonucleotides Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Antisense Oligonucleotides Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Antisense Oligonucleotides Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Antisense Oligonucleotides Consumption Value by Type (2018-2029)
  • 6.2 North America Antisense Oligonucleotides Consumption Value by Application (2018-2029)
  • 6.3 North America Antisense Oligonucleotides Market Size by Country
    • 6.3.1 North America Antisense Oligonucleotides Consumption Value by Country (2018-2029)
    • 6.3.2 United States Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Antisense Oligonucleotides Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Antisense Oligonucleotides Consumption Value by Type (2018-2029)
  • 7.2 Europe Antisense Oligonucleotides Consumption Value by Application (2018-2029)
  • 7.3 Europe Antisense Oligonucleotides Market Size by Country
    • 7.3.1 Europe Antisense Oligonucleotides Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 7.3.3 France Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Antisense Oligonucleotides Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Antisense Oligonucleotides Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Antisense Oligonucleotides Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Antisense Oligonucleotides Market Size by Region
    • 8.3.1 Asia-Pacific Antisense Oligonucleotides Consumption Value by Region (2018-2029)
    • 8.3.2 China Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 8.3.5 India Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Antisense Oligonucleotides Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Antisense Oligonucleotides Consumption Value by Type (2018-2029)
  • 9.2 South America Antisense Oligonucleotides Consumption Value by Application (2018-2029)
  • 9.3 South America Antisense Oligonucleotides Market Size by Country
    • 9.3.1 South America Antisense Oligonucleotides Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Antisense Oligonucleotides Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Antisense Oligonucleotides Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Antisense Oligonucleotides Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Antisense Oligonucleotides Market Size by Country
    • 10.3.1 Middle East & Africa Antisense Oligonucleotides Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Antisense Oligonucleotides Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Antisense Oligonucleotides Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Antisense Oligonucleotides Market Drivers
  • 11.2 Antisense Oligonucleotides Market Restraints
  • 11.3 Antisense Oligonucleotides Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Antisense Oligonucleotides Industry Chain
  • 12.2 Antisense Oligonucleotides Upstream Analysis
  • 12.3 Antisense Oligonucleotides Midstream Analysis
  • 12.4 Antisense Oligonucleotides Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein.
    According to our (Global Info Research) latest study, the global Antisense Oligonucleotides market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    This report is a detailed and comprehensive analysis for global Antisense Oligonucleotides market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Antisense Oligonucleotides market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Antisense Oligonucleotides market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Antisense Oligonucleotides market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Antisense Oligonucleotides market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Antisense Oligonucleotides
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Antisense Oligonucleotides market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ionis Pharmaceuticals, Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals and Antisense Therapeutics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Antisense Oligonucleotides market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    RNA Antisense Oligonucleotides
    DNA Antisense Oligonucleotides
    Market segment by Application
    Hospitals
    Clinic
    Others
    Market segment by players, this report covers
    Ionis Pharmaceuticals
    Sarepta Therapeutics
    Biogen
    Alnylam Pharmaceuticals
    Antisense Therapeutics
    Isarna Therapeutics
    Arrowhead Pharmaceuticals
    Atlantic Pharmaceuticals
    Enzon Pharmaceuticals
    Bio-Path Holdings
    GlaxoSmithKline
    Geron
    ICO Therapeutics
    Marina Biotech
    RXi Pharmaceuticals
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Antisense Oligonucleotides product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Antisense Oligonucleotides, with revenue, gross margin and global market share of Antisense Oligonucleotides from 2018 to 2023.
    Chapter 3, the Antisense Oligonucleotides competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antisense Oligonucleotides market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Antisense Oligonucleotides.
    Chapter 13, to describe Antisense Oligonucleotides research findings and conclusion.

    Buy now